Key Findings
- Purpose
To assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and biologic activity of pociredir in patients with SCD, including effects on fetal hemoglobin (HbF) and hemolysis. - Population (Model)
Planned enrollment up to 70 participants; interim analysis included 16 adults (69% female) with baseline HbF 9.3%. Concurrent hydroxyurea therapy was permitted (5 of 16 participants receiving HU). - Headline Result
- Interim data suggest an acceptable safety profile in early-phase evaluation.
- Dose-dependent increases in HbF were observed, with maximum percentage-point gains reported in the higher-dose cohorts.
- Laboratory markers were consistent with reduced hemolysis.
- Four vaso-occlusive crises occurred (mostly mild); one serious adverse event was reported and considered unrelated to treatment.
- Why It Matters
Increasing HbF remains a core disease-modifying strategy in SCD. Early dose-response pharmacodynamic signals in an ongoing study support further investigation of pociredir as a potential therapeutic option. - Evidence Gaps & Limitations
Interim analysis with small cohort (n = 16), ongoing enrollment, short follow-up, and no comparator arm; clinical efficacy outcomes require confirmation in later-phase trials.
Source: Journal of Sickle Cell Disease “A Phase 1b, Open-label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients With Sickle Cell Disease (SCD): Trial Design”.
Regulatory & Guideline Watch
Current SCD guidance centers on established HbF-inducing therapy such as hydroxyurea. Investigational agents like pociredir remain experimental pending larger controlled trials.